Allianz Asset Management
RYTM icon

Allianz Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Allianz Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Hold
3,000
– – ﹤0.01% 2014
2026
Q1 		$261K Sell
3,000
-5,000
-63% -$486K ﹤0.01% 1918
2025
Q4 		$856K Sell
8,000
-4,100
-34% -$435K ﹤0.01% 1743
2025
Q3 		$1.22M Hold
12,100
– – ﹤0.01% 1667
2025
Q2 		$765K Buy
12,100
+6,000
+98% +$367K ﹤0.01% 1729
2025
Q1 		$323K Hold
6,100
– – ﹤0.01% 2014
2024
Q4 		$341K Buy
6,100
+2,000
+49% +$110K ﹤0.01% 1971
2024
Q3 		$215K Buy
+4,100
New +$196K ﹤0.01% 2068
2024
Q2 		– Sell
-7,400
Closed -$321K – 2238
2024
Q1 		$321K Sell
7,400
-4,500
-38% -$197K ﹤0.01% 1729
2023
Q4 		$547K Hold
11,900
– – ﹤0.01% 1829
2023
Q3 		$273K Hold
11,900
– – ﹤0.01% 2083
2023
Q2 		$196K Hold
11,900
– – ﹤0.01% 1899
2023
Q1 		$212K Hold
11,900
– – ﹤0.01% 2038
2022
Q4 		$347K Hold
11,900
– – ﹤0.01% 1792
2022
Q3 		$292K Buy
+11,900
New +$221K ﹤0.01% 1604

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allianz Asset Management's RYTM Position: Q2 2026 in Review

Allianz Asset Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 3,000 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #2014.

Allianz Asset Management first reported a position in RYTM in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.22M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Allianz Asset Management held 3,000 shares of Rhythm Pharmaceuticals worth $261K as of Q2 2026.
  • Allianz Asset Management left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2014 holding.
  • Allianz Asset Management first reported a position in Rhythm Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Allianz Asset Management's Rhythm Pharmaceuticals position peaked at $1.22M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.